Pavewise | $2,500,000 | (Oct 23, 2025)
ChipAgents | $21,000,000 | (Oct 22, 2025)
Arbor Energy | $55,000,000 | (Oct 22, 2025)
Certified by Founder
Lodge
RheumaGen
start up
United States
- Denver, Colorado
- 10/01/2025
- Series A
- $15,000,000
RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado. For more information, please visit rheumagen.com.
- Industry Biotechnology Research
- Website https://www.rheumagen.com/
- LinkedIn https://www.linkedin.com/company/rheumagen/
Gravwell | $15,400,000 | (Oct 22, 2025)
Ampa | $8,500,000 | (Oct 22, 2025)
Electra Therapeutics | $183,000,000 | (Oct 22, 2025)
Streetbeat | $15,000,000 | (Oct 22, 2025)
Moonshot AI | $10,000,000 | (Oct 22, 2025)
Estuary | $17,000,000 | (Oct 22, 2025)
Tesser | $4,500,000 | (Oct 22, 2025)
CoMind | $60,000,000 | (Oct 21, 2025)
Fourier Health | $8,400,000 | (Oct 21, 2025)